摘要
目的:比较阿立哌唑口崩片与五氟利多暗服药治疗阿尔茨海默病精神和行为障碍的临床疗效与安全性。方法:将阿尔茨海默病的60例患者随机分为研究组(阿立哌唑口崩片暗服药治疗组)和对照组(五氟利多暗服药治疗组)两组,分别给予阿立哌唑口崩片(n=30)与五氟利多(n=30)暗服药治疗,疗程8周,在治疗前及治疗后1、2、4、6、8周末采用AD行为病理学评定量表评定(BEHAVE-AD)和临床疗效总评量表(CGI)评定临床疗效。采用锥体外系不良反应量表(RSESE)、不良反应量表(TESS)评定药物不良反应,并进行比较分析。结果:阿立哌唑口崩片的治疗有效率为66.67%,五氟利多的治疗有效率为63.33%,两组治疗8周后BEHAVE-AD总分和总评均较治疗前显著下降。两组间比较差异无显著性(P>0.05)。阿立哌唑口崩片的不良反应更少。结论:阿立哌唑口崩片与五氟利多暗服药治疗阿尔茨海默病精神和行为障碍疗效相似。阿立哌唑口崩片暗服药依从性好,不良反应轻,疗效及安全性好。
Objective：To evaluate the efficacy of aripiprazole orally disintegrating tablets and penfluridol in the hidden treatment of psychotic and behavioral disturbances in Alzheimer＇s disease.Methods：Both aripiprazole orally disintegrating tablets and penfluridol were hiddenly given to 30 cases of Alzheimer＇s disease with having psychotic and behavioral disturbances for 8 weeks.The efficacy was evaluated with BEHAVE-AD,CGI,and the side effects were recorded with RSESE and TESS in 1,2,4,6,8 weekends.Results：As a whole,the response rate in aripiprazole orally disintegrating tablets of hidden treatment group was 66.67% and penfluridol of hidden treatment group was 63.33%.The score of BEHAVE-AD in aripiprazole orally disintegrating tablets hidden treatment group reduced from 22.24±5.27 to 11.22±3.24 after treatment,while in penfluridol hidden treatment group,from 20.09±5.56 to 10.89±3.27,the difference was no significant （P〉0.05）.There were no serious side effects.Conclusion：Aripiprazole orally disintegrating tablets and penfluridol have good efficacy in the hidden treatment of psychotic and behavioral disturbances in Alzheimer＇s disease,with better compliance and few side effects.
出处
《现代医药卫生》
2010年第18期2757-2759,共3页
Journal of Modern Medicine & Health
关键词
暗服药
阿立哌唑口崩片
阿尔茨海默病
精神和行为障碍
Hidden treatment
Aripiprazole orally disintegrating tablets
Alzheimer＇s disease
Psychotic and behavioral disturbances
